key: cord-0910279-ypispu5k authors: Molica, Stefano; Tam, Constantine; Polliack, Aaron title: Current perspectives regarding SARS‐CoV‐2 vaccination in chronic lymphocytic leukemia date: 2022-03-23 journal: Hematol Oncol DOI: 10.1002/hon.2990 sha: d5e88b82dfb71323923d538481e2b79c2f64c66d doc_id: 910279 cord_uid: ypispu5k In immunocompetent people, the mRNA vaccines BNT162b2 and mRNA‐1273 have been shown to be safe and effective against coronavirus disease of 2019 (COVID‐19). However, results of cohort studies and meta‐analyses have indicated that the degree of humoral response to SARS‐CoV‐2 vaccines in patients with chronic lymphocytic leukemia (CLL) appears to be lower than that observed in the general population. These inadequate responses are mainly related to the disease itself and to the immunosuppressive effect of therapies administered. In the specific context of CLL, enrolling patients with sub‐optimal vaccine‐response in pivotal vaccine trials could be considered as an appropriate approach to improve response to the COVID‐19 vaccine. These clinical trials should also address the issues of regularity and timing of vaccine booster doses or re‐vaccinations, especially in patients undergoing therapy with pathway‐targeting agents and anti‐CD20 monoclonal antibodies. However, since hypogammaglobulinemia is a serious consequence of CLL, patients who do not have a detectable antibody response should be natural candidates for preventive antibody therapy. The coronavirus disease of 2019 (COVID-19) has challenged healthcare systems worldwide and threatened people's general health 1 and until now, the rapid diffusion of the virus has resulted in over five million deaths worldwide. 2 In this respect, age and comorbidities represent the main risk factors for severe respiratory infection leading to death. 3 Since these conditions frequently recur in patients with hematological malignancies, clinical management of these cases deserves special consideration. 4, 5 A recent meta-analysis assessed the risk of death in patients with hematological malignancies and COVID- 19 . 4 This study involved a sample of 3240 mostly hospitalized patients from three continents and reported a 34% death rate. 4 In another cohort of 740 patients with hematological malignancies from Turkey, the case fatality rate (CFR) was considerably higher than that observed in controls matched for age, sex, and comorbidities (13.8% vs. 6.8%). 6 In chronic lymphocytic leukemia (CLL), defects in the innate and adaptive immune responses are evident in almost all patients at an early stage of their disease and may account for the relatively high (31%-33%) CFR related to COVID-19 infection. [7] [8] [9] [10] [11] In addition, the transition from exclusively relying on chemo-immunotherapy to the more frequent use of treatment with novel molecular-targeted agents may impact the existing immunodeficiency of CLL in a different way than chemotherapy. 8 The rapid development of anti-SARS-CoV-2 vaccines offers the general population a chance of clinical protection from SARS-CoV-2 infection, 12 although there are some concerns regarding vaccine efficacy in CLL patients. [13] [14] [15] [16] The current situation presents a challenge In earlier pandemic reports, it was apparent that patients with CLL were more susceptible to SARS-CoV-2 infection and had a higher CFR than the general population. [9] [10] [11] The Campus CLL group (identified on its homepage as an "interactive network of Italian specialists active in the field of CLL") reported a 30.4% CFR in a CLL-specific Italian cohort of 46 COVID-19-infected patients. 9 In a joint survey by Campus CLL and the European Research Initiative on CLL (ERIC), involving 190 patients with CLL and COVID-19, the CFR was 32.5%. 10 The study identified advanced age as a factor related to poor clinical outcome of COVID-19 infection, but the impact of comorbidities and hypogammaglobulinemia was only marginal. 10 They also reported the potential benefit of therapy with Bruton kinase (BTK) inhibitors, which was based on the lower rate of hospitalization observed among patients on therapy with ibrutinib. 10 Another study from the USA, involving 198 patients with COVID-19 and CLL, reported a similar CFR (33%); however, therapy with BTK inhibitors did not affect the severity of COVID-19 infection. 11 Finally, a recent retrospective international analysis of 941 CLL patients diagnosed with COVID-19 from the start of the pandemic to 16 March 2021, reported a CFR of 38.4%. The risk of death was higher for older patients and for those with cardiac failure, while untreated CLL patients had a better chance of survival than those recently treated or on current treatment. 17 An important issue is whether the improvements in clinical outcomes of COVID-19 infection observed in the general population during the second pandemic wave are also evident in patients with CLL. 18 A United States multicenter study analyzed clinical presentation and outcome changes at the different periods of the COVID-19 pandemic by extending the follow-up of previously reported CLL cases and also added patients who were more recently diagnosed. 19 The CFR declined from 35% in the preceding observation period (until December 2020) to 11% in the subsequent observation period. 19 In another study of 60 consecutive patients from a welldefined area in Sweden, outcomes were analyzed during 13 months of the COVID-19 pandemic; in months 1-6 versus months 7-13 of the pandemic, fatalities decreased from 32% to 18%. 20 In the updated Italian CLL Campus study, the CFR remained stable at 25% throughout the different pandemic phases. 21 These results were confirmed in the expanded retrospective international multicenter study of ERIC and Campus CLL, showing no difference in the CFR during the first and second COVID-19 pandemic waves. 17 Overall, these studies that captured mostly hospitalized symptomatic CLL patients without accounting for asymptomatic COVID-19 infections basically overestimated patient CFRs by systematically underestimating the total COVID-19 prevalence in patients with CLL. Other potential biases include patient heterogeneity, mostly relating to differences in treatment status, and disparities in the existing healthcare systems of the countries in which patients were encountered. [9] [10] [11] 19, 20 Earlier studies have revealed that patients with CLL who developed SARS-CoV-2 infection have inadequate antibody responses, anticipating what was later observed for these patients after COVID-19 vaccination. 19, 22 Greenberg and co-workers assessed the extent of antibody response to SARS-CoV-2 vaccines in over 1400 patients with hematological malignancies recruited in a prospective cohort registry in the United States 16 ; among the 650 patients with CLL included in this study, only 64.2% developed a positive antibody response after two doses of mRNA SARS-CoV-2 vaccination. It is interesting to note that 28% of the patients who failed to produce a spike antibody response had received no prior therapy in the preceding two years. 16 Two studies conducted in Israel assessed the efficacy of SARS-CoV-2 mRNA vaccines in patients with CLL. 13, 14 In the first study, conducted within the ERIC framework and including 167 CLL patients, the antibody response rate was 52.2% in treatment-naïve patients and 16.0% in patients on active treatment. 13 In the second study which enrolled 373 CLL patients from nine Israeli medical centers response rate to the BNT162b mRNA COVID-19 vaccine was 61% in treatment-naïve patients and between 23% and 24% in those treated with BTK and BCL-2 inhibitor agents (BTKi and BCL-2i) respectively. 14 23 After the first vaccination dose, 34% of patients had spike-specific antibody responses, compared to 94% in healthy recipients. In patients with CLL, however, antibody responses increased to 75% after the second dose compared to 100% in healthy recipients. 23 In two large trials, lower immunoglobulin concentrations were found to be negative predictors of response to the BNT162b2 mRNA COVID-19 vaccine in patients with CLL, confirming what had previously been reported with the influenza virus vaccine. 13, 14, 24 Furthermore, according to the results of three reports presented at the 2021 American Society Hematology meeting, the rate of seroconversion in CLL patients ranged from 52% to 61%. [25] [26] [27] Overall, the rates of seroconversion after COVID19 vaccination indicate a sub-optimal response to SARS-CoV-2 mRNA vaccines in CLL patients. [22] [23] [24] [25] [26] [27] [28] However, as shown in Figure 1 results are heterogeneous. A potential confounder with the results of these studies is the inclusion of CLL patient cohorts which are also heterogeneous in terms of treatment status at the time of COVID-19 vaccination (Table 1 ). According to the results of a recent metaanalysis, the rate of seroconversion was 73% in treatment-naïve patients but only 29%-32% in patients on therapy with BTKi or BCL2i. 29 These results confirm the detrimental effect of BTKi on the antibody response to de novo antigens, as previously observed with the hepatitis B and influenza vaccine in patients receiving ibrutinib. 30, 31 A practical implication is that COVID-19 vaccination should be administered before initiating therapy with a BTKi. Finally, the rate of seroconversion was only 4% in vaccinated patients within 12 months of their last anti-CD20 antibody infusion. 29 Overall, these results suggest that SARS-CoV-2 vaccination should be offered before starting anti-CD20 therapies. Furthermore, when feasible, physicians should delay administering anti-CD20 monoclonal antibodies to prevent vaccination inefficacy. 32 Another unaddressed issue concerns the relative effectiveness of the SARS-CoV-2 mRNA vaccines in patients with hematological neoplasms compared to matched controls. In a cohort of 32,516 vaccinated patients with hematological neoplasms, which did not include patients with CLL, increased risks of documented COVID-19 infections, COVID-19-related hospitalization, and COVID-19-related deaths were seen when compared to age-, sex-, and comorbiditymatched vaccinated controls. 33 This study indicates that vaccinated patients with hematological neoplasms, particularly those who are on treatment, have worse COVID-19 outcomes than vaccinated individuals with an intact immune system. A possible third approach could be to provide CLL patients with a double dose of the mRNA vaccine. In this respect, it is noteworthy that in patients with multiple myeloma, an anti-influenza vaccination strategy at higher dosages leads to greater serologic hemagglutinin inhibition responses and to more durable influenza-specific immunity. 38 In immunocompromised individuals, the appearance of SARS-CoV-2 strains with immunological escape ability, like the Delta variant (B.1.617.2), is a source of concern. 39 Currently, the extent to which the variant evades vaccine-induced immunity in immunocompromised individuals is still unclear. In a study of 21 healthy controls and 64 patients receiving different immunosuppressive drugs such as rituximab or methotrexate, two doses of BNT162b2 produced a neutralizing response against Alpha and Delta strain of SARS-CoV-2 in 100% of controls. In contrast, only 5% of patients receiving therapy with rituximab developed neutralizing antibodies against the original strain of SARS-CoV-2 and none against the variants. 40 Recent data suggest that humoral protection against the delta variant is indeed markedly impaired in CLL patients. 41 Overall these results suggest that the BNT162b2 vaccine determines an ineffective humoral response in patients with CLL or in those receiving immunosuppressive therapies, indicating the need for optimizing immune protection in these patient subsets. 40, 41 Results obtained with monoclonal antibodies indicate that complementary approaches to protect immunocompromised patients from SARS-CoV-2 infection more effectively are available. 42 47 These data illustrate how difficult it is to produce a panneutralizing monoclonal antibody against SARS-CoV-2. Recent studies on SARS-CoV-2 vaccination in CLL have evaluated the persistence of SARS-CoV-2 antibodies after vaccination. 48, 49 Tadmor and co-workers. 48 have not been sufficiently studied as yet. In healthy controls, a dynamic and integrated emergence of a spike-specific adaptive immune response has been observed, which is characterized by a T cell response sometimes evident before the development of high levels of anti-RBD antibodies. 51 In this regard, a recent study showed that patients with CLL had a lower T cell response to COVID-19 vaccinations than healthy controls, and only three of 21 (14.3%) CLL patients had both a humoral and a T cellular response. 52 In a report addressing the cellular immunogenicity of COVID-19 vaccinations in patients with CLL, spike-specific T cells were detected in two of 4 patients with anti-spike antibodies and in two of three patients without seroconversion. 25 These results suggest that a cellular response may be observed even in the absence of a humoral response. The complex interplay between disease-, patient-, and treatmentrelated factors makes individuals with CLL particularly susceptible to SARS-CoV-2 infection and sparsely responsive to vaccination. Results of cohort studies and meta-analyses indicate that the degree of humoral response to SARS-CoV-2 vaccines in patients with CLL appears to be lower than that observed in the general population. 13 This paper was not funded. Authors do not declare any conflicts of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study. https://orcid.org/0000-0003-2795-6507 The peer review history for this article is available at https://publons. com/publon/10.1002/hon.2990. WHO declares COVID-19 a pandemic Case fatality rate of COVID-19: a systematic review and meta-analysis Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients When CLL meets COVID-19 The outcome of COVID-19 in patients with hematological malignancy A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia Perturbation of the normal immune system in patients with CLL Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL campus Outcomes of COVID-19 in patients with CLL: a multicenter international experience COVID-19 vaccinations: the unknowns, challenges, and hopes Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study Why do COVID death rates seem to be falling? COVID-19 in patients with CLL: improved survival outcomes and update on management strategies Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B-and T-cell immunity during 13 months in consecutive patients Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients A clue to better select chronic lymphocytic leukemia patients with optimal response to BNT162b2 mRNA COVID-19 vaccine Humoral and cellular immunogenicity of COVID-19 vaccinations in patients with CLL Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis Online ahead of print mRNA COVID-19 vaccines in patients with CLL: a systematic review and meta-analysis Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines Ibrutinib may impair serological responses to influenza vaccination When timing is more important than quantity in COVID-19 vaccination Effectiveness of the BNT162b2mRNA Covid-19 vaccine in patients with hematological neoplasms. Blood. 2021:2021013768. Online ahead of print A third anti-SARS-Cov2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia. Haematologica. 2021. Online ahead of print Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard two-dose vaccination Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias Evolution of the SARS-CoV-2 genome and emergence of variants of concern Immunogenicity of BNT162b2 vaccine against the alpha and delta variants in immunocompromised patients Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases Annrheumdis-2021-221508 Impaired neutralization of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia Subcutaneous REGEN-COV antibody combination to prevent Covid-19 Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 OMICRON (B.1.1.529): a new SARS-CoV-2 variant of concern mounting worldwide fear SARS-CoV-2 Omicron BA.2 variant evades neutralization by therapeutic monoclonal antibodies Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia Six months antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia BNT162b2 vaccination induces durable SARS-Cov-2 specific T cells with A stem cell memory Phenotype. Sci Immunol SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia Subcutaneous REGEN-COV antibody combination to prevent Covid-19 Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia